[marcosdumay]

The article paints the FDA as very involved with this. To the point it claims the person that approved the drug moved to work in the company shortly after.

Besides, "stepping back and letting pharma companies innovate" is not the same as not participating. The FDA can make drug development cheap by many means, and the required fiscalization or catching that kind of behavior is not done by increasing the weight of the approval process.